PENTRACOR GMBH - HEALTH FOR THE PORTFOLIO
Pentracor GmbH, a spin-off from the university environment, has been in operation since 2010. With its solution PentraSorb® CRP is a completely new therapeutic, extracorporeal treatment method for the sustained containment of progressive internal tissue damage in patients following acute events such as heart attacks. By filtering the blood plasma outside the body, the so-called C-reactive protein (CRP), which causes tissue damage, is selectively and immediately removed. This gives the medical technology product from Pentracor a unique selling point.